Shares of IDEXX Laboratories surged 18.1% to $650.87 Monday morning after the veterinary diagnostics giant delivered a Q3 earnings report that cleared Wall Street expectations by a wide margin — and then raised its forecast for the rest of the year. The question now: whether the rally prices in a nearly flawless growth story or ignores a quiet concession on profitability.
• A Clean Beat Across the Board Rewarded a Beaten-Down Stock
IDEXX posted non-GAAP earnings of $3.96 per share on revenue of $1.21 billion, beating estimates by $0.25 on EPS and $20 million on revenue.
GAAP EPS hit $4.01, up 18% year over year. The stock had been punished in 2026 — trading at $676.53 to start the year before falling 18.5% to $551.21 heading into the report — so the blowout result triggered a relief rally, snapping the stock back toward levels not seen in months.
• Diagnostics Revenue Keeps Compounding, and That Matters Most
CAG Diagnostics recurring revenue — the subscriptions-and-consumables engine that vets use for blood work, urinalysis, and other tests — grew 11% organically, driven by volume and roughly 4% net price improvement.
Internationally, that figure hit 14%. IDEXX also placed over 1,900 new point-of-care analyzers in clinics, pushing its installed base to nearly 11,000 instruments — each one generating a recurring stream of consumable purchases. This is the core growth loop investors pay a premium for.
• Management Raised Revenue and Earnings Guidance — But Trimmed Margins
Full-year revenue guidance rose to $4.741–$4.767 billion, up $32 million at midpoint.
EPS guidance climbed to $14.96–$15.16, a $0.25 bump at the midpoint, reflecting 15% reported growth. Yet buried in the fine print: IDEXX lowered its full-year operating-margin outlook to 32.1%–32.3%, trimming projected margin expansion to just 50–70 basis points from 70–90 previously. The lower forecast includes costs tied to its recent CoVet acquisition.
• The Valuation Jump Demands Sustained Execution At $650.87, IDEXX is trading at roughly 43× its new midpoint EPS of ~$15.06 — a sharp re-expansion from the ~39× P/E it carried days ago. The raised guidance midpoints still sit slightly below current analyst consensus, and the lowered margin outlook could temper enthusiasm if investors shift focus from the earnings beat to the profitability trajectory. For now, the market is betting that double-digit diagnostic growth and a widening installed base of clinic hardware will keep the premium justified.